Group 1 - The hepatitis concept sector declined by 1.36%, ranking among the top declines in concept sectors, with major declines seen in companies like Hai Chen Pharmaceutical, Hainan Hai Pharmaceutical, and Nuotai Biological [1][2] - Among the 18 stocks that rose, Fu Rui Co., Ltd., Fozi Pharmaceutical, and *ST Shuangcheng led with increases of 6.42%, 5.79%, and 5.03% respectively [1][2] - The hepatitis concept sector experienced a net outflow of 859 million yuan from main funds, with 88 stocks seeing net outflows, and five stocks exceeding 50 million yuan in outflows [2][6] Group 2 - Hai Chen Pharmaceutical had the highest net outflow of main funds at 119 million yuan, followed by Zhongsheng Pharmaceutical, Nuotai Biological, and Lu Kang Pharmaceutical with outflows of 95.25 million yuan, 92.01 million yuan, and 88.21 million yuan respectively [2][6] - The stocks with the highest net inflows included Fu Rui Co., Ltd., Zhongheng Group, and Te Bao Biological, with inflows of 52.72 million yuan, 39.98 million yuan, and 37.06 million yuan respectively [2][6]

截至2025年5月22日，金域实业及其一致行动人所持质押股份情 况如下： 股东 名称 是否为控 股股东或 第一大股 东及其一 致行动人 本次延期 购回 股份数量 （股） 占其所 持股份 比例 （%） 占公司 总股本 比例 （%） 是否 为 限售 股 是否 为 补充 质押 质押 起始日 质押 到期日 延期后质 押到期日 质权人 质押 用途 金域 实业 是 33,000,000 9.17 1.70 否 否 2024 年 5 月 22 日 2025 年 5 月 22 日 2026 年 5 月 22 日 浙商证券 股份有限 公司 自身 融资 需要 合计 33,000,000 9.17 1.70 - - - - - - 一、股东股份质押基本情况 证券代码：002390 证券简称：信邦制药 公告编号：2025-019 贵州信邦制药股份有限公司 关于控股股东部分股份质押延期购回的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称"公司"）于近日收到 公司控股股东贵州金域实业投资合伙企业（有限合伙）（以下简称 "金域实业"）的通知，获悉其 ...

证券代码：002390 证券简称：信邦制药 公告编号：2025-018 贵州信邦制药股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 根据《中华人民共和国公司法》、《上市公司股份回购规则》、 《深圳证券交易所上市公司自律监管指引第 9 号—回购股份》的相关 规定，上市公司回购专用账户中的股份不享有股东大会表决权、利润 分配、公积金转增股本、认购新股和可转换公司债券等权利。因此， 贵州信邦制药股份有限公司回购专用证券账户中 47,445,540 股不参 与此次权益分派。 贵州信邦制药股份有限公司（以下简称"公司"）2024 年年度权 益分派方案已获 2025 年 5 月 7 日召开的 2024 年度股东大会审议通 过，现将权益分派事宜公告如下： 一、股东大会审议通过权益分派情况 1、公司 2024 年度股东大会审议通过的权益分派方案为：以公司 总股本 1,943,851,868 股扣除公司回购专用证券账户已回购的 47,445,540 股后的股本总额 1,896,406,328 股为基数，向全体股东 每 1 ...

Group 1: Company Performance and Challenges - The company faced a decline in gross margin and net profit due to factors such as national drug procurement policies, adjustments in medical insurance settlement methods, and rising raw material prices in 2024 [3] - In Q4 2024, the company reported a net loss of CNY 75.208 million, primarily due to decreased revenue and gross margin in the pharmaceutical distribution and medical services sectors, along with increased non-recurring losses [6] - The management acknowledged the concerns of investors regarding the company's performance and emphasized the importance of protecting investor rights [3] Group 2: Strategic Responses and Future Plans - The management is actively addressing challenges by enhancing medical service quality, optimizing long-term customer accounts in the pharmaceutical distribution sector, and promoting the development of traditional Chinese medicine [3] - The company plans to continue its efforts in market management and operational compliance to ensure long-term development and value creation for investors [3] - The company has implemented a share buyback and cash dividend strategy, distributing a total of CNY 171.2894 million in cash dividends in 2024, which accounted for 168.96% of the net profit attributable to shareholders [6] Group 3: Subsidiary Operations and Legal Matters - The subsidiary, Keke Pharmaceutical, is currently operating normally despite being under investigation, and the company will disclose any significant developments as required [4] - The management reassured investors that the ongoing legal matters would not adversely affect the subsidiary's operations or the company's overall performance [6]

证券代码：002390 证券简称：信邦制药 公告编号：2025-017 贵州信邦制药股份有限公司 关于为下属医院提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称"公司"）于 2025 年 4 月 11 日召开的第九届董事会第六次会议审议通过了《关于 2025 年度 向银行申请授信及担保事项的议案》，董事会同意 2025 年度公司及 合并报表范围内子公司（以下简称"子公司"）向银行申请总额不超 过 210,000 万元的银行综合授信，公司为子公司提供担保额度不超过 170,000 万元，其中为资产负债率低于 70%的子公司提供担保的额度 不超过 120,000 万元，为资产负债率 70%以上的子公司提供担保的额 度不超过 50,000 万元。详情可参见 2025 年 4 月 15 日刊登于中国证 券报、证券时报及巨潮资讯网（http://www.cninfo.com.cn）的《关 于公司 2025 年度向银行申请授信及担保事项的公告》（公告编号： 2025-011）。上述事项已于 2025 年 5 月 7 日经公 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示 1、本次股东大会无增加、否决或修改提案的情况。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 证券代码：002390 证券简称：信邦制药 公告编号：2025-016 贵州信邦制药股份有限公司 2024年度股东大会决议的公告 1、会议通知情况 贵州信邦制药股份有限公司（以下简称"公司"）于 2025 年 4 月 15 日 在 《 中 国 证 券 报 》 、 《 证 券 时 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）刊登了《关于召开 2024 年度股东大 会的公告》（公告编号：2025-013）。 2、会议召集人：公司第九届董事会 3、会议主持人：董事长安吉女士 4、会议时间：2025 年 5 月 7 日 下午 14：00 5、会议地点：贵州省贵阳市乌当区新添大道北段 83 号科开 1 号苑 15 楼会议室 6、股权登记日：2025 年 4 月 28 日 7、召开方式：现场书面投票与网络投票相结合的方式 8、本次股东大会的召集、召开符合《公 ...

国浩律师（上海）事务所 法律意见书 国浩律师（上海）事务所 关于贵州信邦制药股份有限公司 2024 年度股东大会的法律意见书 致：贵州信邦制药股份有限公司 贵州信邦制药股份有限公司（以下简称"公司"）2024 年度股东大会（以下简 称"本次股东大会"）现场会议定于 2025 年 5 月 7 日下午 14：00 在贵州省贵阳市 乌当区新添大道北段 83 号科开 1 号苑 15 楼会议室召开，国浩律师（上海）事务 所（以下简称"本所"）接受公司的委托，指派本所律师出席会议，并依据《中华 人民共和国证券法》、《中华人民共和国公司法》和《贵州信邦制药股份有限公 司章程》（以下简称《公司章程》）出具本法律意见书。 本所律师已经按照有关法律、法规的规定对本次股东大会召集、召开程序是 否合法及是否符合《公司章程》、股东大会召集人资格的合法有效性、出席会议 人员资格的合法有效性和股东大会表决程序、表决结果等发表法律意见。法律意 见书中不存在虚假、严重误导性陈述及重大遗漏，否则愿意承担相应的法律责任。 本所律师是根据对事实的了解和对法律的理解发表法律意见。 本法律意见书依据国家有关法律、法规的规定而出具。 本所律师同意将本法律 ...

Financial Performance - The company's revenue for Q1 2025 was ¥1,441,207,780.35, a decrease of 8.93% compared to ¥1,582,449,461.55 in the same period last year[2] - Net profit attributable to shareholders was ¥41,244,211.17, down 29.89% from ¥58,824,843.56 year-on-year[2] - Basic earnings per share decreased by 33.33% to ¥0.02 from ¥0.03 in the same period last year[2] - Operating profit for the period was CNY 61,765,904.02, compared to CNY 80,596,910.56 in the previous period[16] - The total comprehensive income for the period was CNY 53,861,041.80, down 25% from CNY 71,693,790.38 in the previous period[17] Cash Flow - The net cash flow from operating activities increased significantly by 2,059.91%, reaching ¥55,020,064.59 compared to ¥2,547,325.59 in the previous year[5] - Cash inflow from operating activities totaled CNY 1,445,098,460.85, down 6.3% from CNY 1,541,586,484.20 in the previous period[18] - Cash outflow from operating activities was CNY 1,390,078,396.26, a decrease of 9.7% compared to CNY 1,539,039,158.61 in the previous period[18] - The net cash flow from investing activities was -CNY 34,847,321.93, an improvement from -CNY 61,053,033.28 in the previous period[19] - The net cash flow from financing activities was -CNY 40,714,131.75, an improvement from -CNY 128,283,450.80 in the previous period[19] - The ending cash and cash equivalents balance was CNY 912,180,048.98, compared to CNY 543,901,118.54 in the previous period, indicating an increase[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,016,153,188.07, a slight decrease of 0.13% from ¥9,028,336,478.89 at the end of the previous year[2] - Total liabilities amounted to CNY 2,015,625,494.24, an increase from CNY 2,008,414,826.86 in the previous period[13] - Cash and cash equivalents at the end of the period were CNY 985,249,525.33, down from CNY 1,015,515,313.40 at the beginning of the period[10] - Accounts receivable increased to CNY 2,596,090,541.54 from CNY 2,534,340,405.01[10] - Inventory decreased to CNY 1,015,339,000.49 from CNY 1,060,430,088.41[11] - Non-current assets totaled CNY 3,740,887,305.68, down from CNY 3,776,245,256.87[12] Shareholder Information - The company’s total equity attributable to shareholders increased by 0.61% to ¥6,751,300,632.76 from ¥6,710,056,421.59 at the end of the previous year[2] - The number of ordinary shareholders at the end of the reporting period was 66,968[6] Investment Income and Impairment - The company reported a 100% increase in investment income to ¥101,384.14, attributed to dividends received from investment projects[5] - The company experienced a decrease in credit impairment losses, with a loss of ¥1,582,518.96 compared to a loss of ¥3,343,367.45 in the previous year[5] Return on Equity - The weighted average return on equity was 0.61%, down 0.25 percentage points from 0.86% in the previous year[2] Audit Status - The company’s first quarter report was not audited[20]

证券代码：002390 证券简称：信邦制药 公告编号：2025-015 贵州信邦制药股份有限公司 关于参加投资者集体接待日活动暨2024年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 贵州信邦制药股份有限公司（以下简称"公司"）已于 2025 年 4 月 15 日在巨潮资讯网（www.cninfo.com.cn）披露了《2024 年年 度报告》，为加强公司与投资者的交流互动，便于投资者进一步了 解公司 2024 年度经营情况及其他关切问题，公司将参加在贵州证监 局指导下，贵州证券业协会联合深圳市全景网络有限公司举办的 2025 年贵州辖区上市公司投资者集体接待日（2024 年度业绩说明会） 活动，具体安排如下： 一、业绩说明会的安排 次业绩说明会公司将提前向广大投资者开展问题征集，提问通道自 本公告发出之日起开放至 2025 年 5 月 8 日截止，请通过微信关注 "贵州资本市场"公众号，发送关键词"提问"即可进入专区提问。 公司将在本次说明会上对投资者普遍关注的问题进行回答。 欢迎广大投资者积极参与本次年度业绩说明会。 特此公告。 贵州 ...

Core Viewpoint - Xinfang Pharmaceutical (SZ002390) reported a decline in both revenue and net profit for the year 2024, indicating significant challenges in its business operations [1][3]. Financial Performance - In 2024, Xinfang Pharmaceutical's operating revenue was 6.03 billion yuan, a decrease of 6.63% compared to 2023 [2][3]. - The net profit attributable to shareholders was 101 million yuan, down 64.7% year-on-year, marking the lowest level in nearly six years [2][3]. - The net profit after deducting non-recurring gains and losses was 165 million yuan, a decline of 38.29% from the previous year [2][3]. - The net cash flow from operating activities was 635 million yuan, down 19.69% year-on-year [2][3]. - Basic and diluted earnings per share were both 0.05 yuan, a decrease of 66.67% compared to 0.15 yuan in 2023 [2][3]. Asset and Equity Position - Total assets at the end of 2024 were approximately 9.03 billion yuan, a decrease of 2.34% from the previous year [2][3]. - The net assets attributable to shareholders were about 6.71 billion yuan, down 2.08% year-on-year [2][3]. Segment Performance - The pharmaceutical distribution segment generated 4.75 billion yuan in revenue, a decline of 10.03%, with a gross margin of 9.17% [3][4]. - The medical services segment reported revenue of 1.64 billion yuan, down 8.48%, with a gross margin of 9.55% [3][4]. - The traditional Chinese medicine manufacturing segment achieved revenue of 939 million yuan, an increase of 11.28%, but with a gross margin of 47.89%, down 1.83% [3][4]. Non-Recurring Gains and Losses - In 2024, non-recurring losses amounted to approximately 63.94 million yuan, compared to a gain of 19.33 million yuan in the previous year [5][6]. - The largest component of non-recurring losses was from "other operating income and expenses," totaling 67 million yuan [5][6]. Investment and Other Income - Investment income for the year was approximately 1.30 million yuan, a significant increase of 264.84% compared to the previous year [7]. - Operating expenses decreased by 43.07% in the first three quarters of 2024, indicating a potential improvement in cost management [6][7].